MedPath

Mindfulness Therapy in Inflammatory Bowel Disease

Not Applicable
Completed
Conditions
Bowel Disease
Interventions
Behavioral: Mindfulness
Registration Number
NCT02963246
Lead Sponsor
Cardenal Herrera University
Brief Summary

Aim: To compare the effects of a specific application of Mindfulness vs. Treatment-asusual control group in patients with bowel disease. Design: randomized controlled trial. Setting: Outpatient setting. Population: patients who attended bimonthly check up.

Detailed Description

Background: Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition with a relapsing disease course. Managing the relapsing nature of the disease causes daily stress for IBD patients. Mindfulness-based Cognitive Therapy (MBCT) is an evidence-based psychological program designed to help manage depressive and stress symptoms.

Aim: To compare the effects of a specific application of Mindfulness vs. Treatment-as usual control group in patients with bowel disease.

Outcome measures: quality of life, inflammatory and stress markers. Design: randomized controlled trial. Setting: Outpatient setting. Population: patients who attended bimonthly check up.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • patients with bowel disease diagnostic
  • patients with non active disease symptoms in the last 3 month
  • patients with access to internet and basic informatic knowledge
Exclusion Criteria
  • active disease symptoms
  • planned surgery
  • cognitive impairment
  • previous experience with mindfulness

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Mindfulness groupMindfulnessMindfulness intervention (12 months). Mindfulness based Cognitive Therapy is an evidence-based psychological program designed to help manage depressive and stress symptoms.
Primary Outcome Measures
NameTimeMethod
Quality of life measured with the IBDQ-32 (Inflammatory Bowel Disease Questionnaire)Change from Baseline IBDQ-32 score at 12 months
Secondary Outcome Measures
NameTimeMethod
inflammation stress markers (reactive Protein C and faecal calprotectin)Change from Baseline inflammation stress markers at 12 months

Trial Locations

Locations (1)

Universidad CEU Cardenal Herrera

🇪🇸

Elche, Spain

© Copyright 2025. All Rights Reserved by MedPath